1. Generics Bulletin
  2. >>Business

Reddy’s issues mostly repeats

Five of the eight ‘Form 483’ observations that Dr Reddy’s recently received from the US Food and Drug Administration (FDA) following an audit at the Indian firm’s local oncology formulations plant in Duvvada were repeat issues, according to the Form 483 report that has just been released by the agency.

Five of the eight ‘Form 483’ observations that Dr Reddy’s recently received from the US Food and Drug Administration (FDA) following an audit at the Indian firm’s local oncology formulations plant in Duvvada were repeat issues, according to the Form 483 report that has just been released by the agency.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

More from Business

How To Make The Most Of Your GGB Awards Entries

 
• By Dave Wallace

With the Global Generics & Biosimilars Awards 2025 taking place in Frankfurt this October, we bring you five key pieces of guidance to help ensure that your entries stand out from the competition.

Denosumab Race Heats Up In Europe With Eight More Nods

 
• By Dave Wallace

Denosumab competition is heating up in Europe, with four more companies this month gaining EMA endorsements for their Prolia and Xgeva biosimilar rivals.

Rage Against The Machine: Generics CEOs Slam Systemic Problems In The US

 
• By Dave Wallace

During the “CEOs Unplugged” panel at the AAM’s annual conference in February, leaders from Sandoz, Lupin and Amneal discussed the various ways in which the US framework is making life difficult for generics and biosimilars.